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JSPS KAKENHI, Grant/Award Number: 16K10998; Takeda Science Foundation Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies.
In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel-resistant and castration-resistant prostate cancer (CRPC) because cabazitaxel is often administered as a last resort. However, the mechanism by which cabazitaxel resistance develops is still unclear. C-C motif chemokine ligands (CCL) were shown to contribute to the castration resistance of prostate cancer cells via an autocrine mechanism. Therefore, we focused on CCL as key factors of chemoresistance in prostate cancer cells. We previously established a cabazitaxel-resistant cell line, DU145-TxR/CxR, from a previously established paclitaxel-resistant cell line, DU145-TxR. cDNA microarray analysis revealed that the expression of CCL2 was upregu- is apparently a key contributor to cabazitaxel resistance in prostate cancer cells.
Inhibition of the CCL2-CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC in combination with cabazitaxel.
K E Y W O R D S
apoptosis, cabazitaxel, CCL2, chemoresistance, prostate cancer these patients after developing resistance to docetaxel. 6 Because cabazitaxel is often administered as a last resort in this setting, developing resistance to it is a major challenge in the treatment of patients with CRPC. However, the mechanism by which cabazitaxel resistance develops is still unclear. We previously established a cabazitaxel-resistant cell line, DU145-TxR/CxR, from our previously established paclitaxel-resistant cell line, DU145-TxR. 7 Although the activation of the multidrug resistance gene 1 (MDR1) is believed to play an important role in the development of cabazitaxel resistance in prostate cancer cells, we observed no significant difference in the expression levels between DU145-TxR and DU145-TxR/CxR cells. 7 Identification of the definitive mechanism of development of cabazitaxel resistance is a key imperative to overcome prostate cancer.
C-C motif chemokine ligands (CCL) were shown to contribute to the progression of several cancers, including prostate cancer. 8 The expression of CCL5 in bone stromal cells was shown to contribute to prostate cancer cell migration in the setting of bone metastasis. 9 Furthermore, CCL21 was shown to promote the migration of prostate cancer cells through the phosphorylation of protein kinase p38 in the setting of lymph node metastasis. 10 Moreover, CCL2
was shown to induce castration resistance in prostate cancer cells through an autocrine mechanism. 11 These findings suggest that CCL may be involved in the acquisition of chemoresistance among prostate cancer cells. In this study, we identified some candidate CCL that may induce cabazitaxel resistance in prostate cancer cells on the basis of cDNA microarray data and explored the mechanism of development of cabazitaxel resistance through the CCL2-CCR2 axis.
| MATERIAL S AND ME THODS

| cDNA microarray analysis data
To unravel the mechanisms that contribute to the development of cabazitaxel resistance, we compared gene expression profiles among DU145, DU145-TxR and DU145-TxR/CxR cells using cDNA microarray analysis as previously reported. 7 Briefly, 48 hours after plating of 4 × 10 5 DU145, DU145-TxR and DU145-TxR/CxR cells, total RNA was purified using an RNeasy Mini Kit (Qiagen, Germantown, MD, USA). RNA samples were sent to Takara (Otsu, Japan) and were analyzed using Agilent
Technologies Human 8x60K ver. 2.0 (Santa Clara, CA, USA).
| Reagents and antibodies
Recombinant human CCL2 (rhCCL2) was obtained from BioLegend (San Diego, CA, USA). The following antibodies were used in west- and 72 hours. At the end of the culture period, the cells were trypsinized, harvested and counted using a hemocytometer.
| RNA extraction and RT-PCR analysis
Twenty-four hours after the plating of 1 × 10 5 DU145, DU145-TxR and DU145-TxR-CxR cells on 6-well plates, total RNA was purified with the RNeasy Mini Kit, following the manufacturer's instructions.
The RNA concentration was measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific). First-strand cDNA was prepared from an RNA template (500 ng) using the iScript cDNA 
| Western blotting
Prostate cancer cells were seeded in 6-well plates and allowed to achieve 60%-70% confluence, followed by incubation with rhCCL2, CCR2 antagonist or cabazitaxel. Cell lysates were prepared with M-PER (Mammalian Protein Extraction Reagent, Thermo Fisher Scientific). The soluble lysate (20 μg) was mixed with lithium dodecyl sulfate sample buffer and a sample reducing agent (Thermo Fisher Scientific) and then the components were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes, which were blocked with 1% gelatin in .05% Tween in Tris-buffered saline for 1 hour at room temperature. The membranes were then incubated overnight at 4°C
with primary anti-CCR2, anti-caspase-3, anti-PARP, anti-Bcl-xL or anti-GAPDH antibodies following the manufacturers' instructions.
The membranes were then washed 3 times before incubation with HRP-conjugated anti-rabbit secondary antibodies for 1 hour at room temperature. Protein bands were detected using SuperSignal West
Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).
| ELISA for CCL2
Human CCL2 secretion in a serum-free conditioned medium from DU145, DU145-TxR and DU145-TxR-CxR cells was quantified using a Quantikine Human ELISA Kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Absorbance was measured at 450 nm and was corrected at 540 nm on a microplate reader. 
| Apoptosis assay
| Xenograft study in mice
Intact male SCID mice (aged 6-7 weeks) were obtained from CLEA Japan (Tokyo, Japan). After a 2-week acclimatization period, University, Kanazawa, Japan.
| Statistical analysis
Statistical analyses were performed using the commercially available software GraphPad Prism (GraphPad Software, San Diego, CA, USA). Student's t test was used to assess between-group differences. Significance was defined as *P < .05, **P < .01 and ***P < .001.
| RE SULTS
| CCL2 expression in DU145-TxR and DU125-TxR/CxR cells increased remarkably among the 24 CCL genes
We extracted the available 24 CCL genes from cDNA microarray analysis data. Compared to DU145 cells, the expressions levels of most CCL genes were not increased. However, the expression levels of CCL2 and CCL28 in DU145-TxR cells increased 70-fold and 13-fold, respectively, and the expression levels of CCL1, CCL2 and CCL28 in DU145-TxR/CxR cells increased 5-fold, 43-fold and 11-fold, respectively. We focused on CCL2 as a key factor for the development of cabazitaxel resistance among DU145 cells, because the (Table 1) .
| DU145-TxR and DU145-TxR/CxR cells secreted CCL2 protein abundantly
The Collectively, these findings suggest that the CCL2-CCR2 axis may play a key role in the development of cabazitaxel resistance in DU145 cells. Figure 3A) . Similarly, the CCR2 antagonist alone or cabazitaxel alone hardly increased the apoptosis of DU145-TxR/ CxR cells, whereas a combination of a CCR2 antagonist and cabazitaxel dramatically increased apoptosis compared to cabazitaxel alone ( Figure 3B ).
| CCL2 increased the proliferation rate under treatments with cabazitaxel
| Cabazitaxel induced apoptosis through the induction of cleaved caspase-3 and cleaved PARP
To explore the mechanism of the effect of cabazitaxel, apoptosisassociated protein expression levels were detected by western blotting. The levels of cleaved caspase-3 and cleaved PARP in DU145, DU145-TxR and DU145-TxR/CxR cells were increased in a dose-dependent manner, and the respective intensities showed a strong association with the number of apoptotic cells ( Figure 4A ,B,C). In contrast, the expression level of Bcl-xL (an antiapoptotic protein) in DU145 and DU145-TxR cells was decreased under cabazitaxel treatment in a dose-dependent manner F I G U R E 5 Cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) were inhibited by the activation of the CCL2-CCR2 axis. A-C, The levels of apoptosis-related proteins, caspase-3 and PARP, in DU145, DU145-TxR and DU145-TxR/CxR cells were examined using western blotting. DU145 cells were seeded on 6-well plates and treated with 3 nmol/L cabazitaxel or 10 ng/mL CCL2 or a combination of both (A). DU145-TxR (B) and DU145-TxR/CxR (C) cells were seeded on 6-well plates and treated with 10 nmol/L cabazitaxel or 5 μg/mL CCR2 antagonist or a combination of both ( Figure 4A,B) . The expression of Bcl-xL in DU145-TxR/CxR cells was hardly decreased ( Figure 4C ).
| Cleaved caspase-3 and cleaved PARP were inhibited by the activation of the CCL2-CCR2 axis
To confirm that the CCL2-CCR2 axis plays a key role in cabazitaxel resistance, an rhCCL2 or CCR2 antagonist was added to prostate 
| D ISCUSS I ON
In recent studies, the mechanism of development of docetaxel resistance in prostate cancer cells has been reported 14 ; however, the mechanism of cabazitaxel resistance in prostate cancer cells is
The CCR2 antagonist restored the sensitivity to cabazitaxel in vivo. A, After 2 wk of acclimatization, 2 × 10 6 DU145 cells were implanted subcutaneously in SCID mice. The control group was intraperitoneally injected with 20 μL of DMSO, and the cabazitaxel group was intraperitoneally injected with cabazitaxel weekly (days 0, 7 and 14) at a dose of 7 mg/kg diluted with 20 μL of DMSO (n = 5). The tumor size was measured every other day using a caliper. B, Body weight was measured every other day using a scale. C, After 2 wk of acclimatization, 2 × 10 6 DU145-TxR/CxR cells were implanted subcutaneously in SCID mice. The following groups were compared: control, cabazitaxel alone, CCR2 antagonist alone, and a combination of cabazitaxel and CCR2 antagonist. The control group was injected with 20 μL of DMSO. Cabazitaxel was injected weekly (days 0, 7 and 14) at a dose of 7 mg/kg, and the CCR2 antagonist was injected every other day at a dose of 50 μg/kg (n = 6). The left, middle and right bars on the right side of the graph illustrate the comparison between the combination group and the CCR2 antagonist group, the cabazitaxel group and the control group, respectively. The tumor size was measured every other day using a caliper. D, On day 21, the mice were killed and the tumors extracted. E, Body weight was measured every other day using a scale. Data are shown as means ± SEM yet to be clearly elucidated. Other CCL may be involved in cabazitaxel resistance as the downstream of CCL2. CCL2 was shown to attract macrophages, and these macrophages transform to tumor-associated macrophages in the tumor microenvironment and contribute to cancer progression. 21 Tumor-associated macrophages stimulate prostate cancer cells to secrete CCL17 and CCL22, which increase their migration ability via an autocrine mechanism. 22 The expression level of CCR4 (a common receptor of CCL17 and CCL22) was shown to be associated with the expression level of CCR2 in prostate cancer tissues. In addition, prostate cancer tissues of patients with locally advanced or metastatic cancer show a high expression of CCR4. 22 In addition, CCL17 and CCL22 were shown to activate regulatory T-lymphocytes that inhibit the anticancer cell activity of cytotoxic T-lymphocytes. 23, 24 Hence, further studies with an immunological approach are required to further explore the complex role of CCL in cabazitaxel resistance of prostate cancer cells.
CCL2 also activates signal transducer and activator of transcription 3 (STAT3) and AKT in prostate cancer cells. 11, 25, 26 In the process of developing castration resistance, the inhibition of androgen receptor signaling induces CCL2 secretion from prostate cancer cells, which, in turn, promotes the phosphorylation of STAT3 in an autocrine manner, resulting in an increase of the migratory and invasive ability of prostate cancer cells. 11 Similarly, in the process of developing bicalutamide resistance, CCL2 promotes the phosphorylation of AKT via an autocrine mechanism, which results in an increase in the migratory and invasive ability of prostate cancer cells. 25 Indeed, the activation of AKT contributes to docetaxel resistance via epithelialmesenchymal transition, 27 and these pathways may contribute to cabazitaxel resistance of prostate cancer cells through the activation of the migratory and invasive ability.
Furthermore, because we previously demonstrated that MDR1
promotes cabazitaxel resistance of prostate cancer cells, CCL2
and MDR1 are probably directly or indirectly linked to each other.
Although there are no studies proving a direct linkage between CCL2 and MDR1, STAT3 activation was shown to induce cisplatin resistance of lung cancer cells via the upregulation of MDR1. 28 Moreover, the inhibition of STAT3 and AKT, as the upstream of MDR1, was shown to attenuate paclitaxel resistance of lung cancer cells and adriamycin resistance of breast and colon cancer cells. 29 Paclitaxel disrupts the interaction of STAT3 with tubulin, and CCL2 may restore this interaction via activation of STAT3. 30 Investigating the mechanisms related to STAT3 and AKT pathways may help unravel the mechanism of cabazitaxel resistance of prostate cancer cells.
In conclusion, although this study has a limitation that a single cell line was used for experiments, our data suggest that CCL2 is a contributor to cabazitaxel resistance of prostate cancer cells. The inhibition of the CCL2-CCR2 axis may be a potential candidate for treatment of prostate cancer in combination with cabazitaxel.
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